Overview
Spherix’s coverage of the multiple sclerosis market focuses on the dynamic and expanding landscape of disease modifying treatment. We are uniquely positioned to provide insights at the subtype level informed by prescribing patterns and treatment philosophies as the armamentarium evolves with new branded and generic options.
Services Available
Trending market evolution
Multiple Sclerosis (US) - quarterly, n=100
Multiple Sclerosis (EU) - semiannual, n=250
Multiple Sclerosis (Canada) - semiannual, n=250
Exploring the patient journey
DMT New Starts in MS (US) - annual, n=1,000 patient charts
DMT Switching in MS (US) - annual, n=1,000 patient charts
DMT Switching in MS (EU) - annual, n=1,250 patient charts
Progressive Forms of MS (US) - annual, n=750 patient charts
Benchmarking new brand performance
Zeposia (BMS) in Multiple Sclerosis (US)
Kesimpta (Novartis) in Multiple Sclerosis (US)
Ponvory (Janssen) in Multiple Sclerosis (US)*
*Pending approvals and launch